The effect of trastuzumab emtansine (T-DM1) to the platelets for HER2-positive advanced breast cancer patients

The effect of trastuzumab emtansine (T-DM1) to the platelets for HER2-positive advanced breast cancer patients - The effect of trastuzumab emtansine (T-DM1) to the platelets for HER2-positive advanced breast cancer patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000014750

Enrollment

Registered

2014-08-07

Start date

2014-08-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. metastatic or advanced HER2 positive breast cancer 2. scheduled treatment with T-DM1 3. age >20 years 4. written informed consent

Exclusion criteria

Exclusion criteria: 1. drug allergy to T-DM1 or trastuzumab 2. uncontrollable infection and diabetes mellitus 3. bleeding tendency 4. not suitable for participation with any other reasons

Design outcomes

Primary

Measure	Time frame
The influence of T-DM1 on platelets	—

Secondary

Measure	Time frame
platelet production platelet function bone marrow involvement of breast cancer	—

Countries

Japan

Contacts

Public ContactSatoshi Tamaru

Mie University Hospital Clinical Research Support Center

tamaru3@clin.medic.mie-u.ac.jp+81-59-231-5246

Outcome results